X0306 4 2022-11-16 1 0001664106 LogicBio Therapeutics, Inc. LOGC 0001863053 Gruskin Daniel C/O LOGICBIO THERAPEUTICS, INC. 65 HAYDEN AVE, FLOOR 2 LEXINGTON MA 02421 0 1 0 0 Chief Medical Officer Common Stock 2022-11-16 4 D 0 3331 D 0 D Stock Option (right to buy) 0.70 2022-11-16 4 D 0 140000 D 2032-03-01 Common Stock 140000 0 D Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes. The options were granted on March 1, 2022. The options were scheduled to vest over four years: 25% of the options were scheduled to vest on the first anniversary of the grant date with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Company on each vesting date. At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. /s/ Frederic Chereau, as Attorney-in-Fact 2022-11-17